Harmony Biosciences (HRMY) Misses Q4 EPS by 29c

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.57, $0.29 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $243.8 million versus the consensus estimate of $239.23 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Piper Sandler: 'Amazon.com (AMZN) AMZN Looks Best Positioned'
• RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
• Argus Upgrades Abercrombie & Fitch (ANF) to Buy